Compare · CVRX vs DXCM
CVRX vs DXCM
Side-by-side comparison of CVRx Inc. (CVRX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 116.4x CVRX ($204.0M).
- Over the past year, CVRX is up 4.3% and DXCM is down 13.4% - CVRX leads by 17.6 points.
- CVRX has been more active in the news (5 items in the past 4 weeks vs 4 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- DexCom Inc.
- Price
- $7.83+1.56%
- $61.67+0.20%
- Market cap
- $204.0M
- $23.76B
- 1M return
- -15.90%
- -6.74%
- 1Y return
- +4.26%
- -13.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 5
- 4
- Recent ratings
- 13
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CVRX
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- SEC Form DEFA14A filed by CVRx Inc.
- SEC Form DEF 14A filed by CVRx Inc.
- CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CVRx Reports Preliminary First Quarter 2026 Financial Results
- Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)
- CHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Morrison Gregory
- PRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)
- CHIEF MKTG & STRAT OFFICER Verrastro Paul was granted 45,000 shares and sold $10,146 worth of shares (1,284 units at $7.90), increasing direct ownership by 260% to 60,551 units (SEC Form 4)
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)